Professional research reports powered by Noah AI — grounded in 100M+ sources including PubMed, clinical trials, guidelines, and patents.
This review summarizes the efficacy, safety profile, sequencing considerations, and evolving clinical role of Trodelvy in advanced breast cancer.
Enhertu demonstrates substantial efficacy across HER2-driven malignancies, with meaningful survival benefits but an important risk of interstitial lung disease requiring careful monitoring.
Apixaban provides effective, convenient anticoagulation across approved indications, lowering stroke and bleeding risk while requiring careful dosing, interactions, perioperative management.
Risankizumab shows strong multi-indication efficacy, favorable tolerability, and cross-specialty utility, though IBD use is limited by intravenous induction logistics.
Biktarvy offers durable, guideline-preferred HIV treatment with strong efficacy, a high resistance barrier, HBV activity, and manageable safety, interaction, and use limitations.
Adalimumab shows broad efficacy, established safety, and durable value across indications, while biosimilars and newer mechanisms reshape global adoption.
Tirzepatide delivers substantial, durable weight loss and cardiometabolic benefits with manageable gastrointestinal risks, though long-term safety and access remain important considerations.
Dupilumab inhibits IL-4/IL-13 signaling, demonstrating broad efficacy, acceptable safety, and biomarker-guided utility across multiple type 2 inflammatory diseases populations
Nivolumab, an anti-PD-1 monoclonal antibody, demonstrates durable survival benefits across multiple malignancies, with expanding regulatory approvals and biomarker-guided patient selection optimising its benefit-risk profile.
This review examines the clinical efficacy, safety, biomarker selection, and practical adoption considerations guiding pembrolizumab use across major oncology indications.
Improving outcomes in PDAC appears to depend not only on therapeutic innovation, but also on more consistent delivery of timely, biomarker-informed, multidisciplinary, and equitable care.
HCC management continues to be constrained by surveillance underutilization, delayed diagnosis, inconsistent multidisciplinary care, treatment heterogeneity, and regional disparities, highlighting the need for risk-stratified, systems-level implementation beyond guideline dissemination alone.
Colon cancer outcomes depend on effective care delivery; navigation, outreach, multidisciplinary care, molecular profiling, and structured surveillance may improve survival and equity
This review synthesizes real-world evidence showing that disparities, diagnostic and staging gaps, and uneven implementation of modern therapies continue to compromise outcomes across the cutaneous melanoma care continuum.
Persistent gaps in HPV vaccination, cervical cancer screening, triage, follow-up, and surveillance continue to challenge equitable prevention and better outcomes worldwide.
A global review of leukemia care gaps, highlighting delays, undertreatment, non-adherence, and monitoring inequities that limit real-world outcomes
Persistent gaps in detection, staging, biomarker testing, perioperative care, and treatment access continue to constrain outcomes in gastric and GEJ adenocarcinoma.
Undertreatment in prostate cancer represents a multifaceted challenge characterized by disparities in care delivery, underutilization of definitive and intensified therapies, and incomplete integration of evidence-based, biomarker-guided treatment strategies across disease stages.
Globally, hepatocellular carcinoma is the leading liver cancer subtype, characterized by high fatality, marked regional heterogeneity, male predominance, and changing risk factor profiles.
HPV is strongly linked to cervical and other cancers worldwide, highlighting the importance of vaccination, screening, and surveillance.